Recommendations for drug therapies for relapsing-emitting multiple sclerosis
Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. For patients with relapsing-remitting multiple sclerosis (RRMS), what are the preferred initial pharmacological treatment strategies?2. For patients with RRMS,...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa
Canadian Agency for Drugs and Technologies in Health
October 2013, 2013
|
| Series: | CADTH therapeutic review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Evidence-informed recommendations were developed by the Canadian Drug Expert Committee (CDEC) to address the following policy questions: 1. For patients with relapsing-remitting multiple sclerosis (RRMS), what are the preferred initial pharmacological treatment strategies?2. For patients with RRMS, what are the pharmacological strategies for patients not adequately controlled on initial pharmacotherapy?3. Should combination strategies be considered for treatment of patients with RRMS? If so, what are the appropriate treatment options? |
|---|---|
| Physical Description: | 1 PDF file (ii, 19 pages) |